RetinalGenix Technologies (RetinalGenix Technologies) Cash-to-Debt : 1.02 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is RetinalGenix Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. RetinalGenix Technologies's cash to debt ratio for the quarter that ended in Mar. 2024 was 1.02.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, RetinalGenix Technologies could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for RetinalGenix Technologies's Cash-to-Debt or its related term are showing as below:

RTGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.11 Max: No Debt
Current: 1.02

During the past 4 years, RetinalGenix Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.04. And the median was 0.11.

RTGN's Cash-to-Debt is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.87 vs RTGN: 1.02

RetinalGenix Technologies Cash-to-Debt Historical Data

The historical data trend for RetinalGenix Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

RetinalGenix Technologies Cash-to-Debt Chart

RetinalGenix Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

0.07

RetinalGenix Technologies Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial										0.14	0.04	-	-	1.02

Competitive Comparison of RetinalGenix Technologies's Cash-to-Debt

For the Medical Devices subindustry, RetinalGenix Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RetinalGenix Technologies's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RetinalGenix Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where RetinalGenix Technologies's Cash-to-Debt falls into.

RetinalGenix Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

RetinalGenix Technologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0	/	(0.049	+	0)
	=	0.00

RetinalGenix Technologies's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.05	/	(0.049	+	0)
	=	1.02

RetinalGenix Technologies (OTCPK:RTGN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

RetinalGenix Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of RetinalGenix Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

RetinalGenix Technologies (RetinalGenix Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RetinalGenix Technologies Inc (OTCPK:RTGN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1450 North McDowell Boulevard, Suite 150, Petaluma, CA, USA, 94954

Website

https://www.retinalgenix.com

RetinalGenix Technologies Inc is an ophthalmic research and development company focused on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, Its mission is to prevent vision loss and blindness due to diabetic retinopathy and maculopathy through early detection from the use of two devices: (1) Retinal Imaging Screening Device (RetinalGenixTM), being designed as a portable, high-resolution retinal imaging Diabetic screening system providing a 200-degree field of view without requiring pupil dilation; and (2) RetinalCamTM, being designed as a high-resolution home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available 24/7.